The LMO/LYL1 and TLX3-mutated subgroups have a higher prevalence of ETP-ALL cases [66], and ETP-ALL patients show a similar mutational profile to that of AML patients, with hematopoietic stem-cell like gene expression profiles [67,68]. Here, TLX3 is linked to acute lymphoblastic leukemia.